<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Head injury &#8211; European Clinical Trials Information Network</title>
	<atom:link href="https://clinicaltrials.eu/meddra_pt/head-injury/feed/" rel="self" type="application/rss+xml" />
	<link>https://clinicaltrials.eu</link>
	<description>Bridging Patients with Clinical Trials</description>
	<lastBuildDate>Fri, 12 Jun 2026 10:31:29 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png</url>
	<title>Head injury &#8211; European Clinical Trials Information Network</title>
	<link>https://clinicaltrials.eu</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Study on Naloxegol to Prevent Constipation in Patients with Brain Injury and Opioid Use</title>
		<link>https://clinicaltrials.eu/trial/study-on-naloxegol-to-prevent-constipation-in-patients-with-brain-injury-and-opioid-use/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 29 Apr 2026 14:27:46 +0000</pubDate>
				<guid isPermaLink="false">https://clinicaltrials.eu/trial/study-on-naloxegol-to-prevent-constipation-in-patients-with-brain-injury-and-opioid-use/</guid>

					<description><![CDATA[This clinical trial is focused on patients who have experienced head trauma or a type of bleeding in the brain known as meningeal hemorrhage. These conditions can lead to problems with the movement of food through the digestive system, known as gastrointestinal motility disorders. The study is investigating the use of a medication called Moventig, [&#8230;]]]></description>
										<content:encoded><![CDATA[<p>This clinical trial is focused on patients who have experienced <b>head trauma</b> or a type of bleeding in the brain known as <b>meningeal hemorrhage</b>. These conditions can lead to problems with the movement of food through the digestive system, known as <b>gastrointestinal motility disorders</b>. The study is investigating the use of a medication called <b>Moventig</b>, which contains the active ingredient <b>naloxegol oxalate</b>. This medication is being tested to see if it can help prevent constipation and lung infections in patients who are receiving strong pain medications, known as opioids, while in intensive care.</p>
<p>The purpose of the study is to evaluate how effective <b>naloxegol</b> is in preventing early constipation and lung infections in patients with brain injuries who are being treated with opioids. Participants in the study will receive either the medication or a placebo, which looks like the medication but does not contain the active ingredient. The study will follow patients to see if they experience any bowel movements or lung infections during their hospital stay.</p>
<p>Throughout the study, researchers will monitor various aspects of the patients&#8217; health, such as their ability to meet nutritional goals, the need for additional medications to manage vomiting or constipation, and the length of time they require mechanical ventilation. The study will also track the overall recovery of patients over a period of six months, using a scale called the <b>Glasgow Outcome Scale Extended (GOSE)</b>, which measures recovery after brain injury. The study is expected to continue until September 2026.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
